Transcat, Inc. Announces Financial Results for Fiscal Year 2025 Second Quarter

Transcat, Inc. (NASDAQ: TRNS) has recently disclosed its financial results for the fiscal year 2025 second quarter ended on September 28, 2024. On October 28, 2024, the company issued a press release regarding this matter, detailed in Exhibit 99.1 of its Form 8-K filing. Moreover, on October 29, 2024, Transcat shared slides on its Investor Relations website that will be used during its earnings conference call and webcast scheduled for 11:00 a.m. Eastern Time on the same day. These slides are attached to the Form 8-K as Exhibit 99.2.

It’s crucial to note that the information provided under Item 2.02, comprising Exhibits 99.1 and 99.2, is not considered “filed” under the Securities Exchange Act of 1934, as per the Form 8-K filing. This information is also not subject to liabilities under Section 18 of the Exchange Act or incorporated by reference into any of the company’s filings under the Securities Act of 1933 or the Exchange Act.

In addition, Transcat confirmed that its common stock, with a $0.50 par value, is registered on the Nasdaq Global Market under the symbol TRNS. The company emphasized that the disclosed financial information is essential and will not impact the normal trading of its securities in the market.

Moving forward, it was stated in the Form 8-K filing that the Company will appeal the recent determination by the Nasdaq Listing Qualification Department regarding the delisting notice due to failure to comply with the minimum bid price requirement. HeartCore Enterprises, Inc. (Nasdaq: HTCR), a Tokyo-based enterprise software and data consulting services company, has encountered a similar situation. HeartCore is currently working on complying with the Nasdaq requirements to ensure the continued listing of its common stock.

It is noteworthy that despite the aforementioned challenges, both Transcat and HeartCore Enterprises remain optimistic about their operations and financial performance. Transcat, headquartered in Rochester, New York, continues to focus on delivering shareholder value and aims to address the Nasdaq compliance matters efficiently.

Investors and stakeholders are advised to stay informed about the updates and proceedings related to Transcat and HeartCore Enterprises’ actions towards compliance with the Nasdaq requirements to ensure transparency and regulatory adherence.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Transcat’s 8K filing here.

Transcat Company Profile

Transcat, Inc provides calibration and laboratory instrument services in the United States, Canada, and internationally. It operates through two segments: Service and Distribution. The Service segment offers calibration, repair, inspection, analytical qualification, preventative maintenance, consulting, and other related services.